image:
view more
Credit: Yuan X., Li X., Wang C., et al., (2026). Hallmarks of lung cancer driven by inhalable particulate matter: From cell-intrinsic oncogenic traits to microenvironment remodeling. The Innovation 7(8), 101347.
Lung cancer kills more people than any other cancer, and a rising share of those patients have never smoked. A review in The Innovation argues that the particles they breathe are a carcinogen in their own right, building tumours by a route tobacco does not use and that current screening rules are designed to miss.
Tobacco control has cut smoking rates, yet lung adenocarcinoma in never-smokers keeps climbing, especially in East Asia. Outdoor particulate matter is a Group 1 carcinogen, per the International Agency for Research on Cancer. Pooled cohorts put the hazard ratio at 1.07 to 1.16 per 10 micrograms per cubic metre of PM2.5; a 204-country analysis found risk rising with exposure and, unlike heart disease or COPD, no threshold up to 600 micrograms.
What has been missing is a mechanism. Led by Kezhong Chen at Peking University People's Hospital, an international team of surgeons, immunologists and computational biologists distilled the literature into a framework they call the Twelve Hallmarks of PM-associated lung cancer, layered as initiation, progression and metastasis.
The clinical picture already differs from tobacco's. In a province-wide Taiwanese screening trial of never-smokers, more than 80 percent of positive cases were ground-glass nodules, and 17.9 percent had multiple primary tumours, against the single solid mass typical of smokers. Molecularly these tumours carry more EGFR mutations and APOBEC mutational signatures, no tobacco signature SBS4, and a lower mutation burden.
The framework's central claim is that particles do not merely mutate DNA; they remodel the tissue around mutant cells. In mouse work several of the authors contributed to, PM2.5 drove macrophage infiltration and sustained interleukin-1 beta release, pushing pre-existing EGFR-mutant alveolar cells into a progenitor-like state; it ran as a Nature cover in 2023. The review extends that to twelve features, from vulnerable alveolar type 2 cells, through metabolic rewiring and stemness, to pre-metastatic niches in liver, bone and brain, with chronic inflammation as the hub.
Susceptibility is uneven. In the ESCAPE cohort the hazard ratio for a 10-microgram rise was 1.04 below age 65 and 1.38 above it; in UK Biobank, high polygenic risk plus high exposure amplified risk by 37 percent. The evidence is also inverted: exposure and mortality are heaviest in South Asia, Southeast Asia and Africa, while most mechanistic and cohort studies come from Europe and North America.
The authors are explicit about the limits. This is a synthesis, not a result: no PM-specific biomarker has been validated in patients, and human studies cannot separate particles from poverty, occupation and indoor smoke. Laboratory work often uses roughly three times the realistic dose, and flat cultures cannot mimic a chronic exposure whose effects persist for five to fourteen years after it ends.
"We wanted to trace the multiple layers of that pathway," the authors write, "and to give early screening and intervention for high-risk groups a scientific basis." For a never-smoker whose scan shows a hazy nodule, the consequence is blunter: a clean smoking history is not a clean risk history.
Journal
The Innovation
Method of Research
Literature review
Subject of Research
Not applicable
Article Title
Hallmarks of lung cancer driven by inhalable particulate matter: From cell-intrinsic oncogenic traits to microenvironment remodeling
Article Publication Date
3-Aug-2026
COI Statement
The authors declare no competing interests.